Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada
Treatment with Strontium89 is available immediately in Canada via Named Patient Program
NEW YORK,?Aug. 10, 2021?/PRNewswire/ —?Q BioMed Inc.?(OTCQB:?QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoSolutions Marketing & Management Inc., a well-known distributor in?Canada?providing services and solutions to the nuclear medicine, radioisotope research, pharmaceutical, and medical device industries.?Under the terms of the agreement, isoSolutions has received exclusive rights to distribute Strontium89 in?Canada.
Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer?and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, and lung, as well as others.
In the?Strontium89?pivotal trial, as many as 79% of patients had pain relief with Strontium89, and twice as many patients treated with?Strontium89?had no pain for 3 months compared with placebo. Further, new pain sites were less frequent in patients treated with?Strontium891,2.?Please see Important Safety Information below.
Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy. isoSolutions and Q BioMed will work together to increase the awareness of doctors and patients to the availability of Strontium89. Q BioMed is actively pursuing full regulatory and marketing approval for Strontium89 in Canada?as well as in other markets worldwide.
Kristin Keller, Q BioMed?Chief Commercial Officer, said, “With the improvement of cancer treatments, providing treatment options to patients suffering from painful skeletal metastases is becoming more and more important. We are happy to collaborate with isoSolutions and provide patients in?Canada?with Strontium89, a viable treatment for patients suffering from painful skeletal metastases caused by cancer.”?
References:
1. STRONTIUM CHLORIDE Sr-89 INJECTION, USP THERAPEUTIC [package insert].?Angleton, TX: IsoTherapeutics Group, LLC; 2020.
2. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805-813.
About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Please visit?https://www.QBioMed.com?and sign up for regular updates.??
About isoSolutions Marketing & Management Inc.
isoSolutions Marketing & Management Inc. is an authorized distributor and service provider, offering products, services and solutions to the nuclear medicine, radioisotope research, pharmaceutical and medical device industries and providing a connection to an extensive network of suppliers and resources.
You may visit?www.isosolutions.com?for further details.
?